Access

Patients everywhere need access to the right treatment at the right time.

Because of our unwavering belief that better access leads to better health, Viatris champions policies that reduce barriers to treatment, helping to achieve better health for patients and unlocking value for health systems. Securing stable access to medicine for current and future patients can only be achieved through policy dialogue and collaboration. We are committed to bridging traditional divides in search of solutions that expand patient access and improve the sustainability of our healthcare system.

Realizing the Promise of Biosimilars

Biosimilar medicines have the potential to generate tremendous savings - initially estimated in the U.S. at $54 billion over ten years - that are essential to ensure equitable patient access to biologic therapies. However, the promise of biosimilars has yet to be fully realized.

Discover our Impact

Protecting Access to Medicines

We know that people may encounter many different conditions over their lifetimes. The design and capacity of healthcare systems differ greatly across the more than 165 countries in which we distribute products. But where someone lives or how much money they have shouldn’t determine their access to preventive care, appropriate diagnosis and treatment. Driving policy solutions that address the needs of individuals while better enabling public health systems to function is critical to empowering people worldwide to live healthier, at every stage of life.

Strengthening Resilient Global Supply Chains

Reliable access to medicines depends on strong global supply chains. We are committed to leveraging our diverse global footprint to best meet the needs of patients.
Read More

Preventing Drug Shortages

We know that patients around the world rely on our medicines, and we are committed to doing our part to ensure continuity of supply, including through policy solutions that tackle root causes of supply disruption.
Read More

Fixing the Misguided Medicaid Generics Penalty

The current inflation penalty applied to generic drugs in Medicaid unintentionally jeopardizes access to affordable medicines for patients across the country.
Read More

Enhancing Meaningful Transparency

Policies seeking greater price transparency are well-intentioned but often place burdensome reporting requirements on generic manufacturers, threatening their ability to continue providing access to lower-cost medicines.
Read More

Sustaining the Proper Disposal of Unused Medicine

The proper disposal of unused medicines is essential, but unnecessarily broad legislation mandating drug take-back programs funded only by manufacturers can compromise access to lower-cost medicines.
Read More

Building Healthier Markets

Accounting for 6.4 billion prescriptions, generic medicines saved the U.S. $373 billion in 2021 alone and almost $2.6 trillion over the last decade. Generics and biosimilars represent 91% of prescriptions filled, but only 18.2% of prescription drug spending.

Insurance Coverage of Off-Patent Competitors

Patient access to lower-priced generic or biosimilar competitors is driven by health plans - these medicines should always be made available.
Read More

Modernize Prescription Prescriber Information

Modernizing prescription prescriber information will increase access to timely information, enhance patient safety, and reduce paper waste.
Read More

Intellectual Property

Sustainable access to medicines for patients is best achieved through an appropriate balance between rewarding innovation and promoting healthy, competitive markets.
Read More